Akebia Therapeutics - Stock

Akebia Therapeutics Liabilities 2024

Akebia Therapeutics Liabilities

272.29 M USD

Ticker

AKBA

ISIN

US00972D1054

WKN

A1XF0S

In 2024, Akebia Therapeutics's total liabilities amounted to 272.29 M USD, a -22.38% difference from the 350.8 M USD total liabilities in the previous year.

Akebia Therapeutics Aktienanalyse

What does Akebia Therapeutics do?

Akebia Therapeutics Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, USA. The company was founded in 2007 and focuses on the development and marketing of medications for the treatment of kidney diseases and other diseases. Akebia Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Akebia Therapeutics's Liabilities

Akebia Therapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Akebia Therapeutics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Akebia Therapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Akebia Therapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Akebia Therapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Akebia Therapeutics Stock

What is the level of liabilities of Akebia Therapeutics this year?

Akebia Therapeutics has a debt balance of 272.29 M USD this year.

What were the liabilities of Akebia Therapeutics compared to the previous year?

The liabilities of Akebia Therapeutics have increased by -22.38% dropped compared to the previous year.

What are the consequences of high debt for investors of Akebia Therapeutics?

High liabilities can pose a risk for investors of Akebia Therapeutics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Akebia Therapeutics?

Low liabilities mean that Akebia Therapeutics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Akebia Therapeutics affect the company?

An increase in liabilities of Akebia Therapeutics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Akebia Therapeutics affect the company?

A decrease in the liabilities of Akebia Therapeutics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Akebia Therapeutics?

Some factors that can influence the liabilities of Akebia Therapeutics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Akebia Therapeutics so important for investors?

The liabilities of Akebia Therapeutics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Akebia Therapeutics take to modify the liabilities?

To change its liabilities, Akebia Therapeutics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Akebia Therapeutics pay?

Over the past 12 months, Akebia Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Akebia Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Akebia Therapeutics?

The current dividend yield of Akebia Therapeutics is .

When does Akebia Therapeutics pay dividends?

Akebia Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Akebia Therapeutics?

Akebia Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Akebia Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Akebia Therapeutics located?

Akebia Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Akebia Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Akebia Therapeutics from 6/11/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/11/2024.

When did Akebia Therapeutics pay the last dividend?

The last dividend was paid out on 6/11/2024.

What was the dividend of Akebia Therapeutics in the year 2023?

In the year 2023, Akebia Therapeutics distributed 0 USD as dividends.

In which currency does Akebia Therapeutics pay out the dividend?

The dividends of Akebia Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Akebia Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Akebia Therapeutics

Our stock analysis for Akebia Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Akebia Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.